KPIs & Operating Metrics(New)
Balance Sheet
Cash Flow Statement
Amortization of Deferred ChargesAsset Writedowns and ImpairmentCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Accured ExpensesChange in CashChange in InventoryChange in ReceivablesDepreciation & Amortization (CF)Free Cash FlowGains from Investment SecuritiesGains from Sales and DivestituresNet Cash FlowNet IncomeNon-cash ItemsOther Working Capital ChangesOther financing activitiesShare-based Compensation
Daily Values
Growth Metrics
Income Statement
Others
Ratios

ClearPoint Neuro (CLPT) Net Cash Flow (2018 - 2025)

Historic Net Cash Flow for ClearPoint Neuro (CLPT) over the last 13 years, with Q3 2025 value amounting to -$3.3 million.

  • ClearPoint Neuro's Net Cash Flow rose 7054.65% to -$3.3 million in Q3 2025 from the same period last year, while for Sep 2025 it was $16.8 million, marking a year-over-year increase of 70592.27%. This contributed to the annual value of -$3.1 million for FY2024, which is 3103.91% up from last year.
  • Latest data reveals that ClearPoint Neuro reported Net Cash Flow of -$3.3 million as of Q3 2025, which was up 7054.65% from $29.4 million recorded in Q2 2025.
  • In the past 5 years, ClearPoint Neuro's Net Cash Flow ranged from a high of $44.8 million in Q1 2021 and a low of -$26.1 million during Q2 2022
  • Moreover, its 5-year median value for Net Cash Flow was -$3.3 million (2025), whereas its average is $960631.6.
  • In the last 5 years, ClearPoint Neuro's Net Cash Flow crashed by 68386.32% in 2022 and then skyrocketed by 127073.37% in 2025.
  • Quarter analysis of 5 years shows ClearPoint Neuro's Net Cash Flow stood at -$3.5 million in 2021, then skyrocketed by 351.36% to $8.9 million in 2022, then plummeted by 113.5% to -$1.2 million in 2023, then fell by 26.37% to -$1.5 million in 2024, then crashed by 118.56% to -$3.3 million in 2025.
  • Its Net Cash Flow was -$3.3 million in Q3 2025, compared to $29.4 million in Q2 2025 and -$7.7 million in Q1 2025.